Trial intelligence / Profile preview

Phase 2 study of futibatinib in FGFR-aberrant cancers

NL-OMON52617Phase 2Active, not recruiting

Sponsor

Taiho Oncology

Start

Dec 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1